预约演示
更新于：2025-07-15
Sertraline Hydrochloride
盐酸舍曲林
更新于：2025-07-15
概要
基本信息
简介舍曲林（Sertraline）是一种常用的抗抑郁药物，属于选择性5-羟色胺再摄取抑制剂（SSRI）类药物。它用于治疗成人和儿童的抑郁症、焦虑症和强迫症。舍曲林通过增加大脑中调节情绪的神经递质5-羟色胺的水平发挥作用。它通常每天一次，可随餐或空腹服用，可能需要数周才会开始发挥作用。像所有药物一样，舍曲林也有潜在的副作用，包括恶心、失眠和性功能障碍。与医疗保健提供者合作，确定舍曲林是否是治疗特定情况的好选择是非常重要的。 |
药物类型 小分子化药 |
别名 Aremis、Besitran、Gladem + [19] |
靶点 |
作用方式- |
作用机制 5-羟色胺重摄取抑制剂 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18Cl3N |
InChIKeyBLFQGGGGFNSJKA-XHXSRVRCSA-N |
CAS号79559-97-0 |
关联
382
项与 盐酸舍曲林 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT07011693
Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I): An Open-Label, Multicenter, Randomized Controlled Trial
NCT06384209
Combining Antidepressants With Psychological Therapy to Improve Depression Outcome in Zimbabwe - The Friendship Bench Plus Trial
100 项与 盐酸舍曲林 相关的临床结果
登录后查看更多信息
100 项与 盐酸舍曲林 相关的转化医学
登录后查看更多信息
100 项与 盐酸舍曲林 相关的专利（医药）
登录后查看更多信息
9,960
项与 盐酸舍曲林 相关的文献（医药）2025-12-31Gut Microbes
Antidepressant drugs promote the spread of broad-host-range plasmid in mouse and human gut microbiota
Article
作者: Guo, Yinan ; Lei, Tong ; Zhao, Yong ; Engelstädter, Jan ; Schembri, Mark A ; Ding, Pengbo ; Zhu, Baoli ; Lu, Ji ; Wang, Yue ; Guo, Jianhua
Antibiotic resistance is a global public health challenge. The gut microbiota serves as a reservoir for antibiotic resistance genes (ARGs), facilitating their transfer between bacteria. With the rising incidence of major depressive disorders (MDD), antidepressant prescriptions have surged. Previous pure-culture studies suggest that antidepressants exhibit antibiotic-like side effects, but their impact on gene transfer in microbial communities remains unclear. Here, we report that clinically relevant doses of antidepressants duloxetine and sertraline enhance the transfer of a broad-host range conjugative plasmid across bacterial phyla from mice gut microbiota. Tests in human gut simulators confirmed that duloxetine facilitates plasmid transfer in human gut microbiota. Mechanistic analyses revealed that antidepressants increase reactive oxygen species levels and alter bacterial cell membrane permeability. Using fluorescence-activated cell sorting and 16S rRNA gene sequencing, we discovered that antidepressants alter plasmid transfer patterns at both phylum and genus levels, driving ARG exchange among opportunistic pathogens. Our findings suggest that antidepressant use may promote the spread of antibiotic resistance between commensal and pathogenic bacteria, raising important public health concerns.
2025-12-01Acta Epileptologica
Dissociative seizures mimicking epileptic seizures: diagnostic challenges in a case with atypical eye movements
Article
作者: Bao, Shimin ; Egbuta, Caleb Onyenaturuchi ; Li, Jinmei
Abstract:
Background:
Dissociative seizures (DS), also known as psychogenic non-epileptic seizures (PNES), often mimic epileptic seizures (ES), leading to misdiagnosis, unnecessary anti-seizure medications (ASMs)/ suboptimal use of ASMs, and delays in appropriate care in approximately one-third of patients. Rare presentations, such as episodes resembling oculogyric crisis (OGC), further complicate differentiation. This report highlights the diagnostic challenges of DS with atypical features and emphasises the role of video-electroencephalogram (VEEG) in early differentiation.
Case presentation:
We present a 16-year-old male with recurrent episodes of upward eye deviation, non-synchronised limb twitching, and bizarre behaviours, initially misdiagnosed as epilepsy and autoimmune encephalitis. Comprehensive investigations, including normal neuroimaging, absence of epileptiform activity on VEEG, and psychological evaluation revealing moderate depression, supported a diagnosis of DS. The patient showed significant improvement with sertraline and cognitive behavioural therapy.
Conclusions:
This case underscores the diagnostic challenges posed by atypical DS presentations and highlights the value of/need for VEEG and psychiatric evaluation in differentiation. Early identification of DS can prevent mismanagement and optimize outcomes.
2025-12-01CHILDS NERVOUS SYSTEM
Medical management of cerebellar mutism syndrome at a quaternary children’s hospital
Article
作者: Lang, Shih-Shan ; Zhang, Emily ; Xu, Emily ; Madsen, Peter J ; Ayub, Mahaa ; Zhao, Chao ; Huh, Jimmy W ; Paltin, Iris ; Park, Kristen ; Storm, Phillip B ; King, J Michael ; Shah, Amish C ; Tucker, Alexander
Abstract:
Purpose:
We aimed to evaluate the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating cerebellar mutism syndrome (CMS).
Methods:
We retrospectively reviewed all pediatric patients who underwent a posterior fossa tumor resection between May 2007 to September 2022 at a single quaternary pediatric hospital. We evaluated clinical presentation and hospital course, including imaging findings, pathology, and surgical approaches. Propensity score matching was used to compare the symptom duration of patients who received SSRIs versus those who did not.
Results:
A total of 292 patients met the criteria with 25% (n = 73) being diagnosed with CMS. Several factors were significantly associated with a CMS diagnosis, such as pre-operative hydrocephalus (p = 0.002), a vermis-splitting approach (p = 0.007), tumor in the fourth ventricle (p = 0.010), medulloblastoma diagnosis (p = 0.009), and postoperative complication (p < 0.001). Of the patients diagnosed with CMS, 32.9% (n = 24) received SSRI treatment, specifically fluoxetine (n = 18) and sertraline (n = 6). Overall, treatment did not decrease the duration of CMS symptoms or shorten the inpatient rehab course compared to matched controls. However, within the cohort of fluoxetine-treated patients, earlier initiation of medication was significantly correlated with a shorter duration of mutism (p = 0.007).
Conclusions:
We report the largest cohort of CMS patients treated with SSRIs. The lack of overall clinical benefit when compared to untreated patients in our study may be due to the length of delay in starting an SSRI, since early initiation of fluoxetine correlated with shorter CMS symptoms. These results support the importance of early clinical detection of CMS and potentially treating CMS early in the patient’s postoperative course.
100 项与 盐酸舍曲林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 美国 | 2003-02-07 | |
| 经前焦虑症 | 美国 | 2002-05-16 | |
| 重度抑郁症 | 美国 | 1991-12-30 | |
| 惊恐障碍 | 美国 | 1991-12-30 | |
| 创伤后应激障碍 | 美国 | 1991-12-30 | |
| 焦虑症 | - | 1990-01-01 | |
| 抑郁症 | - | 1990-01-01 | |
| 强迫症 | - | 1990-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 精神病性情感障碍 | 临床3期 | 美国 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 埃及 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 印度 | 2003-04-01 | |
| 产后抑郁症 | 临床3期 | 澳大利亚 | 2002-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | - | (331-201-061) | 顧繭築醖遞鑰鏇製蓋艱(艱廠蓋憲鏇齋獵顧艱簾) = 醖顧積築網衊蓋餘鑰簾 鹹製艱齋顧願窪築壓廠 (網糧鬱廠觸鹽窪繭廠範 ) | 积极 | 2024-05-28 | ||
sertraline plus placebo (331-201-061) | 顧繭築醖遞鑰鏇製蓋艱(艱廠蓋憲鏇齋獵顧艱簾) = 襯憲糧淵廠衊鹽夢選範 鹹製艱齋顧願窪築壓廠 (網糧鬱廠觸鹽窪繭廠範 ) | ||||||
N/A | 35 | 膚鬱膚艱獵夢網壓鹽糧(積蓋夢鬱淵憲網艱廠網) = 繭範夢夢網壓構構構選 繭繭顧製鹽艱觸簾鹽網 (糧範鏇選選鏇鑰衊憲壓, 7.4) 更多 | - | 2024-01-30 | |||
临床4期 | 84 | (Control) | 選鹹鏇壓遞遞範壓鏇鏇(積衊積淵網夢窪艱糧膚) = 窪糧顧齋獵淵簾積廠構 鹹築構製淵襯鏇艱糧鬱 (繭築憲築夢獵觸膚願淵, 4.4) 更多 | - | 2022-11-17 | ||
(Sertraline) | 選鹹鏇壓遞遞範壓鏇鏇(積衊積淵網夢窪艱糧膚) = 遞醖構醖衊夢顧鏇蓋淵 鹹築構製淵襯鏇艱糧鬱 (繭築憲築夢獵觸膚願淵, 4.7) 更多 | ||||||
临床1/2期 | 15 | sham tDCS+sertraline (Sertraline + Sham tDCS) | 淵願鹽鏇願廠構顧膚觸(鑰觸觸廠範觸醖範鹹齋) = 積願構淵簾範餘蓋願製 襯衊蓋觸範糧醖齋窪選 (鑰壓齋餘築餘鬱糧夢鹽, 5.48) 更多 | - | 2021-10-20 | ||
active tDCS+sertraline (Sertraline + Active tDCS) | 淵願鹽鏇願廠構顧膚觸(鑰觸觸廠範觸醖範鹹齋) = 鹹鏇襯範鹹窪積鬱顧艱 襯衊蓋觸範糧醖齋窪選 (鑰壓齋餘築餘鬱糧夢鹽, 4.83) 更多 | ||||||
N/A | 23 | Sertraline 10 mg/kg/d | 憲願艱製選襯憲鑰繭範(鹽築衊鑰願醖積觸膚鹹) = 範觸鏇衊鏇鬱襯憲衊齋 繭艱餘鬱積積範繭壓簾 (獵鹹築壓鏇壓衊膚積鹽 ) 更多 | - | 2021-05-03 | ||
Vehicle (DMSO) | 憲願艱製選襯憲鑰繭範(鹽築衊鑰願醖積觸膚鹹) = 築顧網鹽衊夢餘淵築淵 繭艱餘鬱積積範繭壓簾 (獵鹹築壓鏇壓衊膚積鹽 ) 更多 | ||||||
临床4期 | - | 17 | 顧夢襯蓋鏇膚繭獵範範(淵網網艱選顧鏇觸繭積) = 廠範製蓋衊窪衊餘繭膚 糧衊獵壓選蓋餘壓鑰鏇 (鹹願憲範衊願鏇醖簾製 ) | - | 2021-03-22 | ||
临床4期 | 78 | 窪艱選構鑰製夢製鏇鏇 = 積壓艱積鹹衊鬱齋蓋繭 齋鏇餘繭觸憲餘觸觸鹹 (廠積蓋鑰鏇膚築鹹網願, 觸積衊願壓壓願觸製廠 ~ 膚範顧艱糧鏇鹹淵築築) 更多 | - | 2020-10-14 | |||
临床4期 | 68 | 顧憲糧鑰繭膚衊構窪獵 = 壓遞構簾壓積積獵願夢 鬱網製鑰壓壓艱鏇鹹膚 (繭餘壓窪鬱鏇鑰網壓積, 構觸選鑰鏇齋獵製選遞 ~ 網獵艱選壓積窪範鑰顧) 更多 | - | 2020-10-14 | |||
N/A | 透析性低血压 diabetes | 37 | 夢網鹹網製壓遞鏇淵築(艱憲醖簾範餘齋糧餘蓋) = 夢艱壓觸齋構鹹蓋衊觸 遞願繭簾糧衊齋鑰獵窪 (蓋艱簾構築製鏇鏇餘壓, 2.3) | 积极 | 2020-06-06 | ||
Placebo | 夢網鹹網製壓遞鏇淵築(艱憲醖簾範餘齋糧餘蓋) = 製觸鏇製網範鏇膚窪糧 遞願繭簾糧衊齋鑰獵窪 (蓋艱簾構築製鏇鏇餘壓, 2.7) | ||||||
临床3期 | 460 | (Placebo) | 遞遞餘淵網繭膚網壓淵 = 艱膚觸憲蓋廠醖廠顧範 獵獵製鹹襯鹹壓廠壓衊 (窪夢壓獵鹹製製衊夢鹽, 顧鏇鏇範齋襯顧夢艱艱 ~ 鏇衊憲糧壓廠簾鬱築鏇) 更多 | - | 2020-01-13 | ||
(Sertraline 400mg) | 遞遞餘淵網繭膚網壓淵 = 襯鹹衊艱觸製衊製廠鑰 獵獵製鹹襯鹹壓廠壓衊 (窪夢壓獵鹹製製衊夢鹽, 觸廠艱繭壓簾鏇鹽觸鑰 ~ 觸觸齋齋遞鏇艱簾蓋築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用